Summary
Pfizer Inc. reported strong financial results for the second quarter and first six months of 2025, with total revenues increasing by 10% and 1% respectively, driven by operational growth in key therapeutic areas. Net income attributable to Pfizer Inc. common shareholders surged to $2.91 billion ($0.51 per diluted share) for the quarter and $5.88 billion ($1.03 per diluted share) for the year-to-date period, a significant improvement compared to the prior year. The company's cost-reduction initiatives are demonstrating positive impacts, with Selling, Informational, and Administrative expenses decreasing year-over-year. These results reflect robust performance across its Biopharma segment, with notable contributions from products like the Vyndaqel family, Padcev, Xtandi, and Comirnaty, despite some headwinds from increased manufacturer discounts due to the IRA Medicare Part D Redesign and competitive pressures on certain established products. Pfizer is actively managing its operational efficiency and strategic investments, as evidenced by its ongoing cost realignment and manufacturing optimization programs. The company also made significant business development moves, including an in-licensing agreement for a bispecific antibody targeting PD-1 and VEGF, demonstrating a commitment to expanding its pipeline. The company's financial position remains strong, with substantial cash and equivalents and prudent capital allocation strategies, including dividend payments and share repurchases. While patent expiries and evolving regulatory landscapes, particularly concerning drug pricing, present ongoing challenges, Pfizer's diversified portfolio and strategic investments position it to navigate these complexities.
Financial Highlights
53 data points| Revenue | $14.65B |
| Cost of Revenue | $3.78B |
| Gross Profit | $10.88B |
| SG&A Expenses | $3.42B |
| Interest Expense | $654.00M |
| Net Income | $2.91B |
| EPS (Basic) | $0.51 |
| EPS (Diluted) | $0.51 |
| Shares Outstanding (Basic) | 5.68B |
| Shares Outstanding (Diluted) | 5.71B |
Key Highlights
- 1Total revenues increased by 10% to $14.7 billion in Q2 2025 and by 1% to $28.4 billion in the first six months of 2025, primarily driven by operational growth.
- 2Net income attributable to Pfizer Inc. common shareholders reached $2.91 billion ($0.51 per diluted share) in Q2 2025 and $5.88 billion ($1.03 per diluted share) year-to-date, a significant increase from the prior year.
- 3Selling, Informational, and Administrative expenses decreased by 8% in Q2 and 11% year-to-date, reflecting cost-reduction and productivity initiatives.
- 4Growth in key products such as the Vyndaqel family (+22% YTD), Padcev (+32% YTD), Xtandi (+12% YTD), and Comirnaty (+74% YTD) are contributing significantly to revenue performance.
- 5The company announced a $1.25 billion upfront payment for an exclusive global, ex-China, in-licensing agreement with 3SBio for a bispecific antibody targeting PD-1 and VEGF, signaling continued investment in pipeline expansion.
- 6Pfizer continued its cost-saving programs, including the 'Realigning Our Cost Base Program' and 'Manufacturing Optimization Program', with substantial progress and anticipated future savings.
- 7The company's balance sheet remains strong, with $1.64 billion in cash and cash equivalents and $11.61 billion in short-term investments as of June 29, 2025.